ContraFect (CFRX) Stock Price Up 3.6%

Shares of ContraFect Corp (NASDAQ:CFRX) were up 3.6% on Wednesday . The stock traded as high as $1.70 and last traded at $1.73. Approximately 968,850 shares traded hands during trading, an increase of 357% from the average daily volume of 211,945 shares. The stock had previously closed at $1.67.

The stock has a market cap of $120.06, a P/E ratio of -6.96 and a beta of -0.28.

ContraFect (NASDAQ:CFRX) last posted its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.11) by $0.15. equities analysts forecast that ContraFect Corp will post -0.33 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. 683 Capital Management LLC purchased a new stake in ContraFect during the 3rd quarter valued at about $2,886,000. Fosun International Ltd purchased a new stake in ContraFect during the 3rd quarter valued at about $9,435,000. Finally, Birchview Capital LP grew its stake in ContraFect by 56.5% during the 3rd quarter. Birchview Capital LP now owns 1,135,082 shares of the biotechnology company’s stock valued at $1,260,000 after purchasing an additional 410,000 shares during the last quarter. Institutional investors and hedge funds own 62.46% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “ContraFect (CFRX) Stock Price Up 3.6%” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at

About ContraFect

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.

Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply